Highlights Altimmune, Inc.

Stocks

ALT

US02155H2004

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-07-10 EDT			5-day change	1st Jan Change
3.050 ^USD	-2.24%		-3.48%	-15.51%

07-07	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
06-29	Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell Small Cap Comp Growth Benchmark	CI

Highlights

05-28	Altimmune Presents 48-Week Data From Impact Phase 2b Trial Of Pemvidutide Demonstrating Significant Metabolic Improvements In Patients With MASH	CI
05-27	Altimmune Presents New IMPACT Phase 2b Data Demonstrating Concurrent Improvements Across Multiple Non-Invasive Markers And qFibrosis-Measured Fibrosis Regression With Pemvidutide In MASH At EASL 2026	CI
05-13	Altimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-23	Altimmune Prices $225 Million Public Offering; Shares Fall Pre-Bell	MT
03-05	Altimmune Shares Fall After Q4 Results	MT
03-05	Altimmune, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
01-05	Altimmune, Inc. Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH	CI
01-05	Altimmune receives FDA breakthrough therapy designation for pemvidutide in mash	RE
12-19	Altimmune, Inc. Announces Positive Topline Results from the Impact Phase 2B Mash Trial	CI
12-19	Altimmune's liver disease drug shows benefits in study, but investors remain unimpressed	RE
12-19	Altimmune's drug for a type of liver disease shows benefits in mid-stage study	RE
11-11	Altimmune, Inc. Announces Publication of Impact Phase 2B Trial Data in the Lancet and Concurrent Late-Breaking Oral Presentation At Aasld the Liver Meeting®? 2025	CI
11-07	Altimmune, Inc. Presents Ai-Based Analysis of Liver Fibrosis Reduction from Impact Phase 2B Trial of Pemvidutide Inash in Late-Breaking Poster At Aasld the Liver Meeting®? 2025	CI
11-06	Altimmune Inc files for mixed shelf of up to $400 million - SEC filing	RE
11-06	Altimmune files for offering of common stock of up to $200 million - filing	RE
11-06	Altimmune, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-06	Altimmune Q3 revenue beats expectations	RE
11-03	Altimmune, Inc. Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder	CI
25-08-19	Altimmune, Inc. Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder	CI
25-08-12	Altimmune, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-07-09	Altimmune, Inc. Announces Initiation of Restore Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease	CI
25-06-26	Altimmune shares slump as weight-loss drug's fatty liver trial data disappoints	RE
25-06-25	Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH	CI
25-05-19	Altimmune, Inc. Announces Initiation of RECLAIM Phase 2 Trial Evaluating Efficacy and Safety of Pemvidutide in Alcohol Use Disorder	CI
25-05-13	Altimmune Q1 Net Income USD -19.575 Million	RE